转自：新华财经 新华财经北京11月3日电 2025年11月，A股有124家公司的限售股面临解禁，合计解禁量约为89.52亿股，解禁规模1606.77亿元，环比下降约26.45%，同比下降约44.64%。其中，锐捷网络 从行业分布来看，通信、医药生物、电子行业解禁市值分别位列前三。 此外，共有7家公司、3.9亿限售股于11月迎上市周年解禁，解禁市值为122.62亿元，包括聚星科技、金天钛业、万源通等企业。 逾1600亿元限售股11月解禁 锐捷网络、创新新材解禁规模居前 锐捷网络的解禁市值居首。11月20日，公司将有7亿首发原股东限售股解禁，解禁市值约为527.8亿元，占总股本比例达88%。 | | | | 面同阶经 | | | --- | --- | --- | --- | --- | | 播 | 证券简称 | 证券代码 | 解禁数量(万股) | 解禁市值(亿元 | | 1 | 锐捷网络 | 301165.SZ | 70,000.00 | 527.80 | | വ | 创新新材 | 600361.SH | 228,681.03 | 102.22 | | ന | 华厦服科 | 301267.SZ | 51,117 ...

新华财经北京11月3日电 2025年11月，A股有124家公司的限售股面临解禁，合计解禁量约为89.52亿股，解禁规模1606.77亿元，环比下降约26.45%，同比下 降约44.64%。其中，锐捷网络解禁规模居首，解禁市值超500亿元。 从行业分布来看，通信、医药生物、电子行业解禁市值分别位列前三。 此外，共有7家公司、3.9亿限售股于11月迎上市周年解禁，解禁市值为122.62亿元，包括聚星科技、金天钛业、万源通等企业。 逾1600亿元限售股11月解禁锐捷网络、创新新材解禁规模居前 截至2025年10月30日的数据显示，11月有124只股票面临解禁，合计解禁量为89.52亿股，以2025年10月30日收盘价计算，合计解禁市值1606.77亿元，环比下 降约26.45%，同比下降约44.64%。 | 44 | 海晨股份 | 300873.SZ | 1,726.84 | 3.96 | | --- | --- | --- | --- | --- | | 45 | 红四方 | 603395.SH | 1,140.35 | 3.83 | | 46 | 志高机械 | 920101.BJ | 526.30 | 2.37 ...

Group 1 - The core issue is that Qingyue Technology (688496) is under investigation by the China Securities Regulatory Commission (CSRC) for suspected false financial reporting, which could lead to a forced delisting if found guilty [1][2] - The company reported a total revenue of 476 million yuan for the third quarter of 2025, a year-on-year decrease of 13.64%, and a net profit attributable to shareholders of -43.35 million yuan, an increase of 11.3% year-on-year [1] - The stock closed at 8.94 yuan per share, with a market capitalization of 4.023 billion yuan [1] Group 2 - Next week, 30 stocks will face a total unlock market value of 20.322 billion yuan, with Huaxia Eye Hospital having the largest unlock value of 9.993 billion yuan [4][5] - The highest unlock ratio is for Huaxia Eye Hospital at 60.85%, followed by several other companies with significant unlock ratios [6] - The average stock price of the 30 stocks facing unlock has decreased by 1.89% since October, with some stocks like Transsion Holdings experiencing a significant drop of 19% [9]

Core Viewpoint - Next week, 30 stocks will have their restrictions lifted, with a total market value of 20.322 billion yuan based on the latest closing prices [1] Group 1: Stock Unlocking Details - Huaxia Eye Hospital will have 511 million shares available for trading, primarily consisting of original shareholders' restricted shares, with a market value of 9.993 billion yuan, the highest among the stocks [1] - Yunding Technology follows with 153 million shares to be unlocked, mainly from the placement of shares to targeted investors, with a market value of 1.74 billion yuan [1] Group 2: Unlocking Ratios - Huaxia Eye Hospital has the highest unlocking ratio at 60.85% [1] - Other companies with significant unlocking ratios include Hongbo Pharmaceutical, Naike Equipment, Yunding Technology, Ruina Intelligent, and Gangdi Technology [1]

Investment Rating - The report maintains an "Outperform" rating for Huaxia Eye Hospital Group, with a target price set at 21.08 RMB based on a 40x PE valuation of the 2025 net profit [8][9]. Core Insights - The report forecasts revenue for 2025-2027 at 4.21 billion, 4.63 billion, and 5.15 billion RMB, with growth rates of 4.6%, 9.8%, and 11.3% respectively. Net profit attributable to shareholders is projected at 443 million, 503 million, and 586 million RMB, growing by 3.3%, 13.6%, and 16.6% [8][9]. - The company is focusing on "organic growth + external M&A" strategy, having successfully acquired Chengdu Aidi Eye Hospital in 2024, enhancing its position as a large medical chain with two top-tier eye hospitals [9][10]. - Huaxia Eye Hospital is actively introducing cutting-edge technology and procedures, maintaining a leading position in ophthalmic innovation, particularly in refractive and cataract surgeries [10][11]. - The company is enhancing its medical quality management and research innovation, aiming to create a high-quality service system driven by innovation in eye disease treatment [11]. Financial Summary - The financial summary indicates total revenue for 2023 at 4,013 million RMB, with a projected increase to 4,212 million RMB in 2025, reflecting a growth of 4.6%. Net profit for 2023 is 666 million RMB, expected to decrease to 443 million RMB in 2024 before recovering to 586 million RMB by 2027 [3][5]. - The report highlights a decline in net profit margin from 16.9% in 2023 to 10.5% in 2025, with a gradual recovery to 11.4% by 2027 [5].

Core Insights - Huaxia Eye Hospital (301267.SZ) released its Q3 2025 report, indicating that as of October 28, 2025, 11 institutional investors held a total of 442 million shares, representing 52.60% of the total share capital [1] - The top ten institutional investors collectively held 52.06% of the shares, with a slight decrease of 0.14 percentage points compared to the previous quarter [1] Institutional Holdings - The top ten institutional investors include Huaxia Medical Investment (Xiamen) Co., Ltd., Xiamen Hanwei Equity Investment Partnership (Limited Partnership), and several other Xiamen-based investment firms [1] - One public fund, Huabao Zhongzheng Medical ETF, reported a decrease in holdings by 0.14% compared to the previous quarter [1] - A total of 180 public funds did not disclose their holdings this quarter, including notable funds such as E Fund ChiNext ETF and Southern CSI 500 ETF [1]

Core Viewpoint - Huaxia Eye Hospital (301267.SZ) reported a revenue of 3.272 billion yuan for the first three quarters of 2025, reflecting a year-on-year increase of 2.83% [1] - The net profit attributable to shareholders reached 434 million yuan, marking a year-on-year increase of 3.04% [1] - The net profit excluding non-recurring gains and losses was 423 million yuan, with a year-on-year increase of 1.65% [1] - Basic earnings per share stood at 0.52 yuan [1] Financial Performance - Revenue for the first three quarters: 3.272 billion yuan, up 2.83% year-on-year [1] - Net profit attributable to shareholders: 434 million yuan, up 3.04% year-on-year [1] - Net profit excluding non-recurring items: 423 million yuan, up 1.65% year-on-year [1] - Basic earnings per share: 0.52 yuan [1]

Core Viewpoint - Huaxia Eye Hospital announced the convening of its third board meeting on October 28, 2025, to review and approve the mid-term profit distribution plan for 2025 [2] Summary by Relevant Sections - **Company Announcement** - The company will hold its third board meeting on October 28, 2025, to discuss the mid-term profit distribution proposal [2]

Group 1 - The core viewpoint of the article highlights Huaxia Eye Hospital's financial performance in Q3 2025, showing a revenue increase and profit growth compared to the previous year [1] - For the first three quarters of 2025, the company's revenue reached approximately 3.272 billion yuan, representing a year-on-year increase of 2.83% [1] - The net profit attributable to shareholders was about 434 million yuan, reflecting a year-on-year growth of 3.04% [1] - The basic earnings per share stood at 0.52 yuan, which is a 4% increase compared to the same period last year [1] Group 2 - As of the report date, Huaxia Eye Hospital's market capitalization is 16.3 billion yuan [2] - The A-share market has surpassed 4000 points, indicating a significant market resurgence after a decade of stagnation, with technology leading the market's new "slow bull" pattern [2]

Company Overview - Huaxia Eye Hospital (SZ 301267) announced the convening of its third board meeting on October 28, 2025, to review the mid-year profit distribution plan for 2025 [1] - As of the report, Huaxia Eye Hospital has a market capitalization of 16.3 billion yuan [1] Revenue Composition - For the first half of 2025, the revenue composition of Huaxia Eye Hospital is as follows: - Refractive services account for 36.9% - Comprehensive optometry projects account for 24.04% - Cataract services account for 20.14% - Posterior segment projects account for 12.94% - Other services account for 5.99% [1]